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Abstract
Purpose of Review Inflammation is a key player in a wide
range of cardiovascular and myocardial diseases. Given the
numerous implications of inflammatory processes in disease
initiation and progression, functional imaging modalities in-
cluding positron emission tomography (PET) represent valu-
able diagnostic, prognostic, and monitoring tools in patient
management. Since increased glucose metabolism is a hall-
mark of inflammation, PET using the radiolabeled glucose
analog [18F]-2-deoxy-2-fluoro-d-glucose (FDG) is the main-
stay diagnostic test for nuclear imaging of (cardiac) inflamma-
tion. Recently, new approaches using more specific tracers to
overcome the limited specificity of FDG have emerged.
Recent Findings PET imaging has proven its value in a num-
ber of inflammatory conditions of the heart including myocar-
ditis, endocarditis, sarcoidosis, or reactive changes after myo-
cardial infarction. In infection-related endocarditis, FDG-PET
and white blood cell scintigraphy have been implemented in
current guidelines. FDG-PET is considered as nuclear medical
gold standard in myocarditis, pericarditis, or sarcoidosis.
Novel strategies, including targeting of somatostatin receptors
or C-X-C motif chemokine receptor CXCR4, have shown
promising results in first studies.
Summary Nuclear medicine techniques offer valuable infor-
mation in the assessment of myocardial inflammation. Given
the possibility to directly visualize inflammatory activity, they
represent useful tools for diagnosis, risk stratification, and
therapy monitoring.
Keywords Inflammation . PET . SPECT .Myocardium .
FDG . Leukocyte
Introduction
Inflammation contributes to initiation, progression, and
healing in various cardiovascular diseases. Its implication
has been most thoroughly examined in coronary and vascular
atherosclerosis which is now broadly considered an inflam-
matory disease [1].
Cardiac inflammation can be caused by many different
conditions: endocarditis, defined as infection of the endocar-
dial surface of one or more heart valves or of an intracardiac
device, has experienced rising incidence in the last decade and
is associated with in-hospital mortality rates of 18–23% [2–4].
After myocardial infarction, the balance and orchestration of
regional and systemic inflammation plays a crucial role in left
ventricular remodeling processes and the subsequent risk of
the development of heart failure [5]. Myocarditis, cardiac sar-
coidosis, and amyloidosis are under-diagnosed causes of oth-
erwise unexplained cardiomyopathies.
Compared with conventional methods, new noninvasive
approaches targeting inflammation have the potential to im-
prove the early detection of myocardial inflammation, enable
quantification of disease activity, guide therapeutic interven-
tions, and monitor treatment success. Leukocyte scintigraphy
is highly specific for infection because granulocytes are re-
cruited to the site of infection. Whereas general utility has
been compromised by limited sensitivity, the implementation
of single photon emission computed tomography (SPECT)
imaging has increased diagnostic performance and opened
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new possibilities in settings in which high specificity is need-
ed, e.g., in endocarditis imaging.
Since increased glucose metabolism is—due to overex-
pression of glucose transporters and overproduction of glyco-
lytic enzymes in inflammatory cells—considered a hallmark
of inflammation, positron emission tomography/computed to-
mography (PET/CT) using the [18F]-labeled glucose analog 2-
deoxy-2-fluoro-d-glucose (FDG) is the standard of reference
for molecular imaging of myocardial inflammation.
Indications include endocarditis, myocarditis, or sarcoidosis
but as well the detection of inflammatory changes after acute
myocardial infarction (AMI). However, specificity of FDG is
hampered by physiological glucose uptake of the myocardium
whose suppression requires dedicated patient preparation. In
order to overcome limitations of FDG, a number of promising
alternatives have recently been introduced including imaging
of somatostatin receptors which are overexpressed on the cell
surface of activated macrophages [6]. Furthermore, C-X-C
motif chemokine receptor CXCR4, which is also
overexpressed by leukocytes, plays a role in stem cell traffick-
ing [7, 8], hence representing a suitable target for molecular
imaging. Given the specific nature of their signal, these tracers
might be used for noninvasive depiction of the temporal and
spatial orchestration of myocardial inflammation. It might
thereby be possible to directly assess the extent of inflamma-
tory activity, localize sites of activity, identify therapeutic tar-
gets, and monitor response to therapy.
Myocardial Infarction
Acute myocardial infarction (AMI) most commonly results
from the acute rupture of a coronary atherosclerotic plaque
leading to rapid thrombus formation in the infarct-related epi-
cardial artery and subsequent ischemia distal to the site of
occlusion [9•]. As a consequence, a well-orchestrated immune
response is activated which is crucial for myocardial repair.
Overshooting inflammation however has been shown to be
associated with inferior outcomes [10, 11].
Cardiac magnetic resonance imaging (CMR) in the
clinical setting of AMI can provide information about
location and extent of acute myocardial injury as well as
left ventricular ejection fraction and end-systolic volume
index as important prognostic indicators after AMI [12].
However, no reliable information on inflammatory activi-
ty can be obtained. Because of overexpression of glucose
transporters and overproduction of glycolytic enzymes in
inflammatory cells, PET imaging with FDG is a useful
tool in assessing the level of post-AMI inflammation. In
experimental models of AMI, FDG-PET has been shown
to localize infiltration of metabolically active leukocytes
[13, 14•]. Clinical studies supported these findings, pro-
viding the opportunity to quantify and monitor metabolic
activity in the myocardium after infarction and to gain
prognostic information on patient outcome [15, 16•].
The suppression of physiologic FDG-uptake into
cardiomyocytes is however mandatory to image mono-
cytes or macrophages and requires patient preparation in-
cluding low-glucose diet, fasting, and administration of
heparin [17, 18]. As potential alternatives to FDG, several
novel tracers have been investigated in recent studies: the
radiolabeled amino acid [11C]-methionine, routinely used
for the characterization of brain tumors and other malig-
nancies, could be demonstrated to serially visualize leu-
kocyte infiltration of inflamed myocardial tissue [19].
Since activated macrophages overexpress somatostatin re-
ceptors on the cell surface, the suitability of PET imaging
of inflammatory activity using [68Ga]-labeled somatostat-
in analogs like [68Ga]-DOTA-TATE or [68Ga]-DOTA-
TOC has been investigated in a small clinical pilot trial.
In comparison to CMR, somatostatin receptor-directed
imaging showed a close spatial relation of macrophage
concentration to CMR-detected structural changes and
might therefore serve as a more specific marker of mac-
rophage activity [20]. However, pre-clinical experiments
in mice questioned the usefulness of this approach [21].
Targeting macrophages is also possible by using
radiolabeled mannose, an isomer of glucose that is taken
up by macrophages through glucose transporters.
Additionally, mannose receptors have been described to
be expressed on a subset of macrophages [22, 23].
Feasibility of this approach has been shown in atheroscle-
rosis imaging [24•] and may be transferrable also to other
settings like AMI.
Another recent approach includes imaging of the C-X-C
motif chemokine receptor 4 (CXCR4)/stromal cell-derived
factor (SDF) -1α axis which has been shown to play a pivotal
role in the recruitment and homing of stem- and progenitor
cells to the infarct zone [25, 26]. Local up-regulation of
CXCR4 in concert with SDF-1α expression after AMI has
been demonstrated to be related to stem cell homing and ben-
eficial outcomes [27–30]. Correspondingly, single systemic
treatment with AMD3100, a CXCR4 antagonist, has been
shown to result in prolonged bone marrow progenitor cell
mobilization and consequently improved recovery from
ischemia/reperfusion injury [31]. Additionally, CXCR4 has
been described to be routinely expressed on various immune
cells and might therefore be involved in the orchestration of
the balance between post-infarct inflammation and its resolu-
tion [32, 33].
Hence, individual CXCR4 expression after AMI might
serve as both a prognostic marker as well as a therapeutic
target. Since the advent of a radiolabeled CXCR4-ligand
for PET imaging [34] and proof-of-concept for visualiza-
tion of CXCR4-expression in oncology patients [35–38],
some small studies have tried to investigate the translation
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of CXCR4-imaging to AMI: local up-regulation of the
receptor in the inflamed myocardium as well as in bone
marrow and spleen could be demonstrated [39, 40].
Animal models suggested that the imaging signal was
mostly created by inflammatory infiltrates as opposed to
recruited stem cells (Fig. 1; [40]). Further research to elu-
cidate the potential prognostic and theranostic value of
CXCR4 imaging is warranted though.
Information on underlying pathways that might also be
targetable for therapeutic interventions might be obtained by
imaging P-selectin using [68Ga]-labeled fucoidan, a
polysaccharidic ligand of P-selectin with a nanomolar affinity.
General feasibility of this approach has been described for
vulnerable plaque imaging but might also be transferable to
the setting of AMI [41]. Alternative approaches try to image
matrix metalloproteinases that are critical in the pathogenesis
of disease [16•, 42] or increased expression of αVβ3 integrin
as a marker of cardiac repair using the novel PET probe [18F]-
Fluciclatide [43].
Endocarditis
Early diagnosis of infective endocarditis (IE) remains chal-
lenging. Essentially, IE should be suspected in all patients
presenting with fever of unknown origin, particularly if it is
associated with laboratory signs of infection, anemia, micro-
scopic hematuria, or septic embolic manifestations. The
Modified Duke Criteria as the current gold standard include
clinical, microbiological, and echocardiographic findings and
have proven an overall sensitivity of about 80% [44•].
However, limitations, especially in patients with prosthetic
valves (PV) and implantable cardiac electronic devices
(ICED) have been reported [45] and can sum up to 24% of
Fig. 1 Validation of [68Ga]-Pentixafor-PET signal in a murine
myocardial infarction model. a Autoradiography of short-axis sections
at 3 days after myocardial infarction (MI), without (top) and with
(bottom) blockade by co-injected AMD3100. Specific [68Ga]-Pentixafor
accumulation can be identified in the blue-stained infarct territory
(Masson trichrome stain (right)). b CD68 and Ly6G immunostaining
(brown ) demons t r a t e s i n f i l t r a t ion o f mac rophages and
polymorphonuclear leukocytes at 3 days post-MI. c Flow cytometry
confirms increased numbers of CD45+ leukocytes in the left ventricle.
Reprinted from [40] by permission of Elsevier/JACC: Cardiovascular
Imaging
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misclassifications [44•]. Advanced imaging techniques for
early and sensitive diagnosis of IE are therefore valuable tools
in clinical practice. Combining FDG-PET/CT with the
Modified Duke Criteria resulted in increased sensitivity with
no major change in specificity [46••]. Whereas FDG-PET is
unreliable in the setting of native valve endocarditis [47•], it
accurately diagnoses prosthetic valve endocarditis and sys-
temic complications of IE [47•–54]. Acknowledging this util-
ity, in 2015 FDG-PET/CT was included in the guidelines of
the European Society of Cardiology as a major criterion for
diagnosing IE in patients with prosthetic valves [55•]. An
option to further improve FDG-PET imaging is the incorpo-
ration of CT angiography into the PET/CT scan, resulting in
91% sensitivity, 91% specificity, and 93% positive and 88%
negative predictive values [53••]. However, specificity of the
method may be limited due to artifacts from metal implants or
due to the non-specific biologic tracer signal [56, 57]. As a
more specific alternative to FDG-PET/CT, the ESC guidelines
included SPECT/CT imaging with radiolabeled autologous
white blood cells (WBC). Whereas this technique has proven
its value in detection of endocarditis [58–60], general applica-
tion was compromised by limited sensitivity due to a weak
signal from the valvular target region and difficult localization
of inflammatory foci. The specificity of leukocyte scintigra-
phy with SPECT/CT could be particularly useful when diag-
nostic uncertainty remains after echocardiography and FDG-
PET/CT, especially in patients who have had cardiac surgery
within the past 4 weeks [56, 57, 61, 62].
Additionally, the recent advent of a novel SPECT technology
which incorporates a sensitive, heart-focused design with the
advantages of cadmium-zinc-telluride (CZT) solid-state detectors
seems to infer significant improvements in radionuclide imaging.
In an elegant approach combining [111In]-labeledWBC imaging
with a simultaneously acquired perfusion study to improve local-
ization of inflammatory hot spots relative to the perfusion-
defined valve plane, a German group could demonstrate superior
imaging quality as well as increased reader confidence for detec-
tion of inflammatory foci (Fig. 2; [63•]).
As another possibility to discriminate between infectious and
inflammatory causes of endocarditis, new, more bacteria-specific
tracers like carbohydrates exclusively metabolized by bacteria or
antibodies directed against components of the bacterial cell mem-
brane, e.g., the pilin protein component of the pilin structure of
Enterococcus faecalis are being developed [64].
Cardiac Implantable Electronic Device (CIED)
Infections Including Implantable Cardioverter
Defibrillator (ICD), Pacemaker-Related
and Ventricular Assist Device-Related Infections
Cardiac implantable electronic devices (CIED) have been in-
creasingly used over the last years [55•]. Infection rates are
reported to be as high as 1–3% and are associated with a 1-
year mortality greater than 10% [65]. Whereas echocardiog-
raphy is the first line imaging modality for the assessment of
supposed CIED infection, its use is severely limited in the
investigation of extra-cardiac leads and device pockets. Both
FDG-PET/CT and leukocyte scintigraphy with SPECT/CT
have proven additional value for diagnosis of ICD- or
pacemaker-related infections. FDG-PET/CT has been shown
to be especially useful for diagnosis of pocket infection (87–
91% sensitivity, 93–100% specificity, 97% PPV, 81% NPV),
but is less reliable for diagnosis of lead infection or device-
related infective endocarditis (24–100% sensitivity, 79–100%
specificity, 66–100% PPV, 73–100% NPV) [66–68].
Nevertheless, in the clinical context of suspected device-
related infection, increased and heterogeneous FDG-uptake
along a lead appears to be a reliable sign of active infection
[66]. Furthermore, presence of a focal hotspot is considered
the best criterion of lead infection [69]. Of note, as with all
applications involving FDG, accuracy of the examination de-
pends on patient preparation and the interval post-implanta-
tion. Mild, unspecific FDG-uptake in patients with an ICD or
pacemaker without suspected infection in the acute phase
(≤2 months) after cardiac surgery has been reported [57].
Additionally, attenuation artifacts due to metal implants must
be avoided by careful scrutiny of non-attenuation corrected
images.
Both FDG-PET/CT and leukocyte scintigraphy with
SPECT/CT seem to be beneficial in the diagnosis of ventric-
ular assist device (LVAD)-related infection [70, 71]. FDG-
PET/CT is especially sensitive for device infection (Fig. 3).
In a small retrospective study, sensitivity for LVAD infection
was 100% and specificity 80%. Additionally, in 75% of cases,
PET imaging had an impact on patient management [72].
Leukocyte scintigraphy with SPECT/CT in LVAD infection
has been reported to yield sensitivity, specificity, and positive
and negative predictive values of up to 100% each. Moreover,
in 23% of cases, otherwise unsuspected extra-cardiac compli-
cations could be revealed [71]. The role of FDG-PET-CT in
the investigation of extra-cardiac complications of CIED in-
fection has also been investigated. In a retrospective study in
patients with suspected CIED infection, whole-body PETalso
identified distant septic emboli or metastatic infection in 28%
of patients [73]. These results could be confirmed in a pro-
spective study in patients with known lead endocarditis [74].
In this cohort, FDG-PET-CT found septic emboli in 10 pa-
tients (29%), including 7 cases of spondylodiscitis, 4 of which
were not clinically apparent at that point in time and resulted
in significant modifications to therapy.
In order to further improve diagnostic accuracy, dual time
point protocols for FDG-PET imaging have been proposed.
The idea is that imaging at a later time point compensates for
background-uptake and might improve accuracy [66, 67, 75].
However, data are limited and studies in other inflammatory
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and infectious diseases argue against an added value of this
approach [76, 77].
Myocarditis
There are many causes for myocarditis, viral infections
being the most common. Further etiologies include other
types of infections, autoimmune disorders, or drug inter-
actions. The clinical manifestations of myocarditis are
highly variable, ranging from subclinical disease to sud-
den death. The variability in presentation reflects the
variability in histological disease severity, etiology, and
disease stage at presentation. Myocardial inflammation
may be focal or diffuse, involving any or all cardiac
chambers. Endomyocardial biopsy (EMB) is currently
the gold standard for diagnosing myocarditis with, how-
ever, very low sensitivity of only 20–30% and a signif-
icant associated procedural risk [78, 79].
CMR is considered the standard imaging modality in the
noninvasive diagnosis of myocarditis as it enables detection of
various features of myocarditis, including inflammatory hy-
peremia and edema, myocyte necrosis and scar, changes in
ventricular size and geometry, regional and global wall motion
abnormalities, and identification of accompanying pericardial
effusion [80]. CMR criteria for diagnosis of myocarditis have
been summarized as the so-called Lake Louise criteria [81].
However, CMR has its limitations which are particularly ap-
parent in chronic myocarditis with diagnostic accuracies as
low as 50% [82]. Additionally, standard CMR may be insen-
sitive for the detection of inflammatory activity, which is crit-
ical for monitoring therapeutic responses to prevent secondary
tissue alterations.
FDG-PET/CT—after adequate patient preparation—can
visualize acute myocardial inflammation to suggest active
myocarditis. PET imaging may help to differentiate between
active and chronic disease and working protocols have been
established [83–85]. In a prospective study enrolling 65 pa-
tients with suspected myocarditis, FDG-PET was in good
agreement with CMR findings [86]. Given the low yield of
random EMB, PET-guided myocardial biopsy may be another
application for FDG-PET/CT, as shown for other diseases [87,
88]. CMR and FDG-PET/CT seem complimentary in nature
[89] and thus the investigation of the incremental value of
integrated PET/MRI for diagnosing myocarditis is an active
field of research [84, 90, 91].
Fig. 2 Example of a patient with suspected endocarditis after aortic valve
replacement undergoing dual isotope single photon emission computed
tomography/computed tomography (SPECT/CT) with simultaneous
radiolabeled leukocyte and perfusion imaging. Planar white blood cell
scans fail to reveal a valvular focus. Conventional SPECT/CT images
using radiolabeled leukocytes suggest a hot spot in the region of the
artificial valve, but are limited by low counts and noise. Dual isotope
images show a focal accumulation adjacent to the implant, consistent
with endocarditis (arrows). At surgery, an abscess was identified under
the right coronary artery ostium, matching the hot spot on the scan.
Reprinted from [62] by permission of Oxford University Press/
European Heart Journal
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In order to overcome limited specificity of FDG, novel
PET tracers for imaging of myocarditis are currently investi-
gated. In a rat model of autoimmunemyocarditis, feasibility of
[11C]-methionine-PET imaging for the detection of cardiac
inflammation could recently be demonstrated. Methionine ac-
cumulation co-localized with histologically confirmed cardiac
inflammatory lesions and [18F]-FDG-uptake, indicating that
[11C]-methionine-PET might represent a promising imaging
agent for the noninvasive diagnosis of myocarditis (Fig. 4;
[92]). Another new approach needing further evaluation in-
cludes targeting of somatostatin receptor 2 and has yielded
encouraging results in a clinical pilot study [20].
Pericarditis
The causes of pericarditis, acute or chronic inflammation of
the pericardium, are manifold and include infection (viral,
bacterial, or fungal), myocardial infarction, trauma, malignan-
cy (primary pericardial neoplasms, pericardial metastasis, or
paraneoplastic syndrome), autoimmune and inflammatory
disease, or metabolic disturbance (uremia). Pericarditis can
also be iatrogenic, either postoperative or as a side effect of
medication. Radiation therapy or idiopathic causes are other
possible origins. Although the etiology is varying, the pericar-
dium has a relatively non-specific response to these different
causes: inflammation of the pericardial layers and increased
production of pericardial fluids are the most common and
often manifest themselves as chest pain.
Echocardiography as the first line of cardiac imaging in the
diagnosis or work-up of pericarditis reveals pericardial effu-
sion, pericardial thickening, and septal bounce. Generally,
computed tomography and CMR also permit evaluation of
pericardial effusion and thickening and permit better differen-
tiation of pericardium and pericardial fluid [93].
The use of FDG-PET/CT in pericarditis is generally comple-
mentary and demonstrates its ability to detect inflammatory tis-
sue even in the absence of obvious anatomical changes [94, 95].
Non-infectious and inflammatory pericarditis presents with a
mild tomoderate FDG-uptakewithin the pericardium,with either
Fig. 3 Value of FDG-PET/CT in
left ventricular assist device
(LVAD) infection. Display of a
45-year-old male patient with
familial non-ischemic dilated
cardiomyopathy status post-
LVAD implantation. At 6 months
after implantation, the patient
reported pain, purulent discharge,
and non-healing at the driveline
exit site. The driveline culture
revealed coagulase-negative
staphylococcus aureus and yeast.
PET/CT images show intense
linear FDG-uptake along the
driveline (open arrowhead) and
percutaneous exit (solid
arrowhead) that is compatible
with driveline LVAD infection.
The patient underwent revision of
the driveline and subsequent
urgent heart transplantation due to
failed response to antibiotic
treatment. Reprinted from [69] by
permission of Elsevier/JACC:
Cardiovascular Imaging
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a diffuse or focal on diffuse pattern of uptake. Only little infor-
mation is available on the utility of FDG-PET in differential
diagnosis of the underlying causes of pericarditis. Some studies
reported on the possibility to differentiate infectious/
inflammatory pericardial disease from neoplastic/metastatic dis-
ease as malignancy often presents with intense metabolic activity
[96]. In a retrospective analysis of patients with tuberculous and
idiopathic pericarditis, maximum standardized uptake values
were significantly higher in tuberculosis patients (13.5 vs. 3.0,
P<0.001) [97]. Constrictive or effusive constrictive pericarditis,
an uncommon complication of chemotherapy, can present with
mild and diffuse pericardial FDG-uptake [94]. Additionally, peri-
carditis associated with increased metabolism of the wall of the
large vessels like the thoracic or abdominal aorta can be caused
by underlying vasculitis [98, 99].
Cardiac Sarcoidosis
Sarcoidosis is a granulomatous disorder of unknown etiology.
Most commonly affecting lymph nodes and lungs, it can
involve any organ system [100]. Though debated, cardiac in-
volvement is more frequent than previously reported [101,
102] and represents one of the leading causes of death by
sarcoidosis in Japan and the USA [103]. Due to the multifocal,
patchy pattern of myocardial sarcoid involvement, the sensi-
tivity of endomyocardial biopsy (EMB) is as low as 20–30%
[78]. In clinical practice, the Guidelines of the Japanese
Ministry of Health and Welfare (JMHWG) which include
clinical as well as imaging-based criteria serve as the gold
standard for diagnosis of cardiac sarcoidosis (CS) [104].
Though not included in JMHWG, PET/CT using FDG is by
far the most commonly used nuclear medicine imaging tech-
nique and has mostly replaced [67Ga]-scintigraphy for assess-
ment of CS [101, 102, 105••, 106].
In comparison to CMR, advantages of FDG-PET (as in
other indications) include the biologic nature of the imaging
signal, the potential to identify cardiac and extra-cardiac sar-
coidosis involvement, and the feasibility of imaging patients
with electrical devices or impaired kidney function. Typically,
CS manifests as a patchy, focal uptake pattern and FDG-PET/
CT has been demonstrated to reliably detect active cardiac and
Fig. 4 [11C]-methionine-PET in
a rodent myocarditis model. a
Representative [11C]-methionine-
PET images 30 min after
intravenous tracer administration.
Strong focal cardiac [11C]-
methionine-uptake was observed
in experimental autoimmune
myocarditis (EAM) rats but not in
control animals. Extra-cardiac
tracer-accumulation in thymus
(asterisk) and the liver (arrows)
was noted in both EAM and
control rats. b Cardiac tracer-
uptake in EAM rats (black bar)
was significantly higher than that
in controls (white bar). c
Representative short-axis PET
images and time–activity curves
of dynamic PET imaging in EAM
rat. Ten to 20 min after
administration, tracer-uptake
increased in heart together with
rapid clearance of blood activity.
Cardiac signals remained stable
for 30–40 min. Gray scale images
serve as reference for location of
heart. Reprinted from [91] by
permission of the Journal of
Nuclear Medicine
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extra-cardiac sarcoidosis with sensitivities of 81–89% and
specificities of 78–82%, respectively (Fig. 5; [106, 107]).
FDG-PET is thereby often combined with radionuclide
perfusion imaging and electrocardiographic gating in order
to rule out coronary artery disease or identify resting perfusion
defects suggestive of inflammation-induced tissue damage
Fig. 5 Classification of cardiac PET/CT perfusion and metabolism imaging. Reprinted from [104] by permission of Elsevier/Journal of the American
College of Cardiology
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[108, 109]. Additionally, FDG-PET/CT in combination with
perfusion imaging has proven its value to determine the prog-
nosis of CS patients [105••], guiding EMB [88] and in
predicting response to and monitoring therapy [110]. In the
future, combined FDG-PET/CMR imaging may prove bene-
ficial by combining the strengths of both techniques [111].
Again, physiologic myocardial FDG-uptake requires dedicat-
ed patient preparation to avoid the pitfall of inadequately sup-
pressed basal uptake. Protocols include prolonged fasting, dietary
modifications (high-fat, low-carbohydrate meals), or application
of heparin prior to imaging [17, 112–116]. In order to overcome
disadvantages of FDG, more specific radiotracers such as so-
matostatin receptor-ligands have been investigated in small pilot
trials (Fig. 6; [117–119]). Though very preliminary in nature,
other alternatives include hypoxia displaying agents like [18F]-
fluoromisonidazole (FMISO) [120] or proliferation markers like
3′-deoxy-3′-[18F]-fluorothymidine (FLT) [121].
Cardiac Amyloidosis
Cardiac amyloidosis (CA) is a rare form of cardiomyopathy
that is characterized by extracellular deposition of fibrils that
are composed of lowmolecular weight subunits of a variety of
serum proteins. Although over 25 different amyloidogenic
proteins have been described, the three most common types
of amyloidosis (defined by their precursor proteins) are light–
chain (AL), familial or senile (ATTR), and secondary (AA)
amyloidosis. CA most commonly manifests as heart failure,
characterized by dyspnea and edema. In its end stage, it pre-
sents itself as restrictive cardiomyopathy with a very poor
prognosis. Definite diagnosis requires either amyloid deposits
on endomyocardial biopsy or, in patients with appropriate
cardiac findings, amyloid deposits on histologic examination
of a biopsy from other tissues (e.g., abdominal fat pad, rectum,
or kidney).
Echocardiography is the initial noninvasive test of choice
to diagnose cardiac amyloidosis but suffers from limited spec-
ificity [122]. CMR is sensitive and can provide typical pattern
of amyloid cardiomyopathy but is strongly limited in patients
with moderate to severe kidney disease. Radionuclide bone
scintigraphy with technetium-labeled bisphosphonates has
long been anecdotally reported to localize to cardiac amyloid
deposits. Radionuclide scintigraphy has been reported to be
sensitive and specific for imaging cardiac ATTR amyloid and
may identify cardiac ATTR amyloid deposits early in the
course of the disease [123••, 124]. In a recent multi-center trial
including 1217 patients with suspected cardiac amyloidosis,
the combination of increased myocardial scintigraphic
radiotracer-uptake and the absence of a monoclonal protein
in serum or urine had a specificity and positive predictive
value for cardiac ATTR amyloidosis of 100% [123••].
However, scintigraphy cannot reliably detect other types of
CA and cannot be quantitatively used for therapy monitoring.
As a potential PET substitute for bisphosphonate-based
tracers, general feasibility of amyloid imaging using
[18F]NaF has been described in single case series whereas
another report failed to identify increased tracer uptake in
Fig. 6 Macrophage-directed positron emission tomography/computed
tomography (PET/CT) using a somatostatin receptor (SSTR) specific
ligand ([68Ga]-DOTA-TOC) in cardiac sarcoidosis. A 54-year-old
patient with suspected atypical myocarditis was referred. Coronary
artery disease was excluded by coronary angiography. Cardiac magnetic
resonance imaging (CMR) revealed acute myocardial damage of the
septal and anterior wall in T2 and contrast-enhanced images (a). PET/
CTusing [68Ga]-DOTA-TOC showed corresponding areas of abnormally
increased tracer-uptake consistent with inflammatory changes (b, c;
arrows). Additionally, enlarged mediastinal lymph nodes and
pulmonary nodular lesions were documented. Suspected sarcoidosis
was confirmed by transbronchial biopsy. Ten months after treatment
initiation, a response of pulmonary (d; insert—baseline CT) and cardiac
involvement (e, f) could be recorded. Reprinted from [118] by permission
of Oxford University Press/European Heart Journal
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ATTR patients [125–127]. Further studies are needed to fur-
ther investigate the potential value of [18F]NaF PET in CA.
Little data available have demonstrated a rather limited role
for FDG PET in imaging of CA [128, 129]. To date, the most
promising alternatives include more amyloid specific tracers
like 11C-labeled Pittsburgh B (PiB) compound [130, 131] as
well as 18F-labeled compounds such as Florbetapir [132, 133]
and Florbetaben [134]. All studies reported on promising re-
sults in diagnosis of CA. Furthermore, since lower myocardial
uptake of [11C]PiB in AL amyloidosis patients who had re-
cently undergone chemotherapy for monoclonal gammopathy
when compared to patients with CA but no prior chemother-
apy could be observed, amyloid-directed PET might also be
used in therapy monitoring as a surrogate marker of active
light chain deposition in the myocardium [130].
Conclusion
Myocardial inflammation is the endpoint of various different
diseases and pathologic conditions. With FDG-PET/CT and
leukocyte scintigraphy being the techniques most commonly
used, nuclear medical imaging techniques are powerful tools
in diagnosis, risk stratification, and therapy monitoring. Novel
approaches including bacteria-specific imaging agents,
targeting of somatostatin receptors, or C-X-C motif chemo-
kine receptor CXCR4 can help to overcome limitations of
standard functional imaging techniques and have demonstrat-
ed encouraging results in pilot studies.
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